The Added Value of Newer Antipsychotics. Workshop. Antwerp (BEL), 1996/05/13.
Schizophrenia is an expensive illness, with hospitalization representing a major cost of treatment.
To evaluate new drugs and management strategies for schizophrenia, we must have reliable measures of outcomes and costs.
Cost-outcome evaluations are particularly important because they allow comparisons of the potential costs and consequences of various strategies.
The best estimates of outcome use batteries of instruments to score the well-being of patients and their caregivers.
Dimensions of well-being include clinical status, functional status, access to resources and opportunities, subjective quality of life, family well-being, and patient satisfaction with services.
The best overall outcome may involve trade-offs between different dimensions (eg, moving a patient from hospital-based care to community-based care may improve the patient's quality of life but increase family burden).
Although measuring direct costs of schizophrenia is reasonably straightforward, indirect costs are more difficult to measure.
The cost of pain and suffering (intangible costs) caused by schizophrenia for an individual patient or family is seldom assessed, although quality-of-life measures may provide some information.
Increased costs of treatments in one area (eg, medication) may well be offset by reduced expenditures in another (eg, hospitalization). (...)
Mots-clés Pascal : Schizophrénie, Chimiothérapie, Traitement, Psychotrope, Hospitalisation, Analyse coût, Economie santé, Qualité vie, Grande Bretagne, Royaume Uni, Europe, Homme, Psychose
Mots-clés Pascal anglais : Schizophrenia, Chemotherapy, Treatment, Psychotropic, Hospitalization, Cost analysis, Health economy, Quality of life, Great Britain, United Kingdom, Europe, Human, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0228515
Code Inist : 002B02B03. Création : 11/06/1997.